30
CARDIOVASCULAR
hamburger
JETi Hydrodynamic Thrombectomy System

Percutaneous mechanical thrombectomy single-session treatment of patients with symptomatic venous thrombosis

Overview: Prospective Pilot Study

Razavi et al., JVIR 2021.

Background
Catheter directed thrombolytics (CDT) often require prolonged exposure to thrombolytic agents which can increase bleed risk. CDT typically requires inpatient care making the treatment inappropriate for outpatient settings.

Objective
To investigate the short-term results of single-session treatment of iliocaval and iliofemoral venous thrombosis using the JETi™ Peripheral Thrombectomy System and evaluate potential for treatment on an outpatient basis.

Methods
Prospective pilot study of 47 patients (53 limbs) who presented with symptomatic iliocaval or iliofemoral venous thromboembolism and subsequently underwent percutaneous mechanical thrombectomy with the intention to treat in a single-session. Obstructive lesions were treated with adjunctive therapy, including balloon angioplasty and stenting, as needed.

Endpoints
Reestablishment of unobstructed flow in a single-session, freedom from major adverse events (MAE), improvement in the clot burden utilizing the VRI scoring system and device-related adverse events.

Clinical Outcomes

Overall, single-session unobstructed flow was reestablished in 89% of limbs with no major adverse events through 30 days. Including patients requiring requiring catheter directed thrombolytics (CDT), restoration of flow was successfully achieved in 94% of treated segments.

Segment Flow Restoration: JETi™ Alone Flow Restoration: JETi™ + Stent*
Iliocaval 86% (12/14) 100% (14/14)
Iliofemoral 75% (27/36) 92% (33/36)
Femoropopliteal 100% (3/3) N/A

*Data includes patients who underwent overnight CDT.

Unobstructed flow was re-established in 89% of limbs in a single-session.

JETi Single Session Thrombosis Treatment Unobstructed Flow Reestablished Data

Single-session treatment with the JETi™ thrombectomy device may reduce the risk of bleeding when compared with CDT and eliminate the need for overnight admission in the majority of cases.

JETi Single Session Thrombosis Treatment Eliminates Overnight Admission Data

Restoration of flow was achieved in 94% of treated segments.

JETi Single Session Thrombosis Treatment Restoration of Flow Data
Request a Demo

Reference:

Razavi et al., JVIR. 2021.

MAT-2209357 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.